HCM
LFCR icon

Highbridge Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Highbridge Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-18,357
Closed -$197K – 1508
2016
Q2 		$197K Buy
+18,357
New +$203K ﹤0.01% 1235

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

Highbridge Capital Management's LFCR Position: Q3 2016 in Review

Highbridge Capital Management sold out of Lifecore Biomedical (LFCR) in Q3 2016, closing a stake of 18,357 shares — an estimated $197K sold.

Highbridge Capital Management first reported a position in LFCR in Q2 2016 and held it in 1 quarter. The position peaked at $197K in Q2 2016. 93 funds tracked by Wall St. Rank hold LFCR as of Q3 2016.

  • Highbridge Capital Management reported no remaining Lifecore Biomedical position as of Q3 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 18,357 Lifecore Biomedical shares in Q3 2016, an estimated $197K.
  • Highbridge Capital Management first reported a position in Lifecore Biomedical in Q2 2016 and held it in 1 quarter.
  • Highbridge Capital Management's Lifecore Biomedical position peaked at $197K in Q2 2016.
  • 93 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2016.

Based on Highbridge Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.